Sélégiline And NotA. A. Boulton
List of bibliographic references
Number of relevant bibliographic references: 17.| Ident. | Authors (with country if any) | Title |
|---|---|---|
| 000094 | Mee-Sook Song [Canada] ; Dmitriy Matveychuk [Canada] ; Erin M. Mackenzie [Canada] ; Maryana Duchcherer [Canada] ; Darrell D. Mousseau [Canada] ; Glen B. Baker [Canada] | An update on amine oxidase inhibitors: Multifaceted drugs |
| 000B63 | Andis Klegeris [Canada] ; Patrick L. Mcgeer [Canada] | R-(-)-deprenyl inhibits monocytic THP-1 cell neurotoxicity independently of monoamine oxidase inhibition |
| 000C37 | K. Kitani [Japon] ; S. Kanai [Japon] ; G. O. Ivy [Canada] ; M. C. Carrillo [Argentine] | Pharmacological modifications of endogenous antioxidant enzymes with special reference to the effects of deprenyl : a possible antioxidant strategy |
| 000C45 | D. L. Gelowitz [États-Unis] ; I. A. Paterson [Canada] | Neuronal sparing and behavioral effects of the antiapoptotic drug, (-)deprenyl, following kainic acid administration |
| 000D53 | I. H. Richard [États-Unis] ; R. Kurlan [États-Unis] ; C. Tanner [États-Unis] ; S. Factor [États-Unis] ; J. Hubble [États-Unis] ; O. Suchowersky [Canada] ; C. Waters [États-Unis] | Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease |
| 000D60 | C.-T. Lai [Canada] ; P. H. Yu [Canada] | R(-)-deprenyl potentiates dopamine induced cytotoxicity toward catecholaminergic neuroblastoma SH-SY5Y cells |
| 000D64 | S. Rohatagi [États-Unis] ; J. S. Barrett [États-Unis] ; K. E. Dewitt [États-Unis] ; D. Lessard [Canada] ; R. J. Morales [États-Unis] | Pharmacokinetic evaluation of a selegiline pulsatile oral delivery system |
| 000D77 | C. Thiffault [Canada] ; L. Lamarre-Theroux [Canada] ; R. Quirion [Canada] ; J. Poirier [Canada] | L-Deprenyl and MDL72974 do not improve the recovery of dopaminergic cells following systemic administration of MPTP in mouse |
| 000E16 | W. G. Tatton [Canada] ; R. M. E. Chalmers-Redman [Canada] | Modulation of gene expression rather than monoamine oxidase inhibition : (-)-Deprenyl-related compounds in controlling neurodegeneration |
| 000E67 | C. Thiffault [Canada] ; N. Aumont ; R. Quirion [Canada] ; J. Poirier | Effect of MPTP and L-deprenyl on antioxidant enzymes and lipid peroxidation levels in mouse brain |
| 000E88 | E. Scarr [Canada] ; D. M. Wingerchuk ; A. V. Juorio ; I. A. Paterson | The effects of monoamine oxidase B inhibition on dopamine metabolism in rats with nigro-striatal lesions |
| 000F00 | P. H. Yu [Canada] | Pharmacological and clinical implications of MAO-B inhibitors |
| 000F36 | M. Takada [Canada] ; T. Sugimoto ; T. Hattori [Canada] | MPTP neurotoxicity to cerebellar Purkinje cells in mice |
| 000F68 | M. Schulzer [Canada] ; E. Mark ; D. B. Calne | The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic |
| 001015 | W. G. Tatton [Canada] ; C. E. Greenwood | Rescue of dying neurons : a new action for deprenyl in MPTP parkinsonism |
| 001032 | O. S. Kofman [Canada] | Deprenyl : protective vs. symptomatic effect |
| 001146 | A. E. Lang | Manipulating the dopaminergic system in Parkinson's disease |
| This area was generated with Dilib version V0.6.29. |  |